Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.

2C , across the range of tumor types evaluated in this phase 1 study, a trend was observed in which patients with lower expression levels of MDMX -short were more likely to achieve disease control (CR, PR, or SD as best overall response) than were patients with higher MDMX -short levels; however, this association did not reach statistical significance.

also in 111,027 other papers